Literature DB >> 19125248

Silencing CD147 inhibits tumor progression and increases chemosensitivity in murine lymphoid neoplasm P388D1 cells.

Li Jia1, Wei Wei, Jun Cao, Henggui Xu, Xiaoyan Miao, Jianing Zhang.   

Abstract

Overexpression of extracellular matrix metalloproteinase inducer (EMMPRIN or CD147), a member glycoprotein enriched on the surface of many malignant tumor cells, promotes tumor progression and confers resistance to some chemotherapeutic drugs. To investigate the possible role of CD147 in the macrophage-like lymphoid neoplasm P388D1 cells progression, we used RNA interference approach to silence CD147 expression. The results showed that silencing of CD147 in P388D1 cells impeded the expression of MMP11 at both mRNA and protein levels. The reduced CD147 expression also resulted in reductions in tumorigenicity, as well as decreased in regional lymph node metastasis. Furthermore, the down-regulation of CD147 expression sensitized cells to be more sensitive to chemotherapeutic drugs. Treatment of tumor cells with U-0126, an inhibitor of mitogen-activated protein kinase/Erk, also down-regulated the expression of MMP11. Our current results indicate that the expression of CD147 functionally mediates tumor progression and is a potential target for therapeutic anti-cancer drugs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19125248     DOI: 10.1007/s00277-008-0678-2

Source DB:  PubMed          Journal:  Ann Hematol        ISSN: 0939-5555            Impact factor:   3.673


  11 in total

1.  Expression of CD147 and Lewis y antigen in ovarian cancer and their relationship to drug resistance.

Authors:  Jian Gao; Zhenhua Hu; Juanjuan Liu; Dawo Liu; Yanyan Wang; Mingbo Cai; Danye Zhang; Mingzi Tan; Bei Lin
Journal:  Med Oncol       Date:  2014-04-02       Impact factor: 3.064

2.  Extracellular matrix metalloproteinase inducer is a negative prognostic factor of pediatric medulloblastoma.

Authors:  Tongwei Chu; Xiaoyang Chen; Jie Yu; Jianwen Xiao; Zhou Fu
Journal:  Pathol Oncol Res       Date:  2011-03-31       Impact factor: 3.201

3.  Expressions of CD147, MMP-2 and MMP-9 in laryngeal carcinoma and its correlation with poor prognosis.

Authors:  Xiaoxia Gou; Haixia Chen; Feng Jin; Weili Wu; Yuanyuan Li; Jinhua Long; Xiuyun Gong; Mengyalan Luo; Ting Bi; Zhuolin Li; Qianyong He
Journal:  Pathol Oncol Res       Date:  2013-12-20       Impact factor: 3.201

Review 4.  Eviction from the sanctuary: Development of targeted therapy against cell adhesion molecules in acute lymphoblastic leukemia.

Authors:  Sonali P Barwe; Anthony Quagliano; Anilkumar Gopalakrishnapillai
Journal:  Semin Oncol       Date:  2017-07-11       Impact factor: 4.929

5.  Co-expression of CD147/EMMPRIN with monocarboxylate transporters and multiple drug resistance proteins is associated with epithelial ovarian cancer progression.

Authors:  Hongmin Chen; Li Wang; Julia Beretov; Jingli Hao; Weiwei Xiao; Yong Li
Journal:  Clin Exp Metastasis       Date:  2010-07-24       Impact factor: 5.150

6.  Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma.

Authors:  Qiang Lu; Gang Lv; Andre Kim; Jong-Myung Ha; Suhkman Kim
Journal:  Oncol Lett       Date:  2012-10-19       Impact factor: 2.967

7.  RNAi-mediated silencing of CD147 inhibits tumor cell proliferation, invasion and increases chemosensitivity to cisplatin in SGC7901 cells in vitro.

Authors:  Bo Wang; Yong-Fei Xu; Bang-Shun He; Yu-Qin Pan; Li-Rong Zhang; Chan Zhu; Li-Li Qu; Shu-Kui Wang
Journal:  J Exp Clin Cancer Res       Date:  2010-06-03

8.  The clinicopathological significance and prognostic value of EMMPRIN overexpression in cancers: evidence from 39 cohort studies.

Authors:  Hengwei Fan; Wanwan Yi; Chenxing Wang; Jisheng Wang
Journal:  Oncotarget       Date:  2017-07-31

Review 9.  Mini-Review: Can the Metastatic Cascade Be Inhibited by Targeting CD147/EMMPRIN to Prevent Tumor Recurrence?

Authors:  Michal A Rahat
Journal:  Front Immunol       Date:  2022-03-28       Impact factor: 7.561

10.  EMMPRIN is an independent negative prognostic factor for patients with astrocytic glioma.

Authors:  Li Tian; Yang Zhang; Yu Chen; Min Cai; Hailong Dong; Lize Xiong
Journal:  PLoS One       Date:  2013-03-13       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.